MedTrace Logo

Right/Left Discrimination Training on Fibromyalgia Patients

NCT05915598 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-06-23

No results posted yet for this study

Summary

To determine whether a targeted right/left discrimination training program can improve pain perception and functional disability in fibromyalgia patients.

Conditions

  • Fibromyalgia

Interventions

OTHER

Right/left discrimination training

Participants will use recognize app by Neuro-orthopedic institute (NOI) for daily right/left discrimination training. The training will include visual and auditory stimuli, with tasks such as identifying the laterality of images and sounds. Participants will engage in training for 20 minutes per day, 5 days per week, over a six-week period. Weekly monitoring and feedback will be provided by the research team

OTHER

usual care

Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group. Follow-up assessments: Participants in the control group will undergo the same follow-up assessments as the intervention group to evaluate changes in pain perception, functional disability, and cognitive function.

Sponsors & Collaborators

  • Ahram Canadian University

    lead OTHER

Principal Investigators

  • Amal Fawzy, Ph.d · Faculty of Physical Therapy, Ahram Canadian University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-25
Primary Completion
2024-07-01
Completion
2024-08-04

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05915598 on ClinicalTrials.gov